成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 105047-45-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 105047-45-8
Chemical Structure| 105047-45-8
Structure of 105047-45-8 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 105047-45-8 ]

Related Doc. of [ 105047-45-8 ]

Alternatived Products of [ 105047-45-8 ]
Product Citations

Product Details of [ 105047-45-8 ]

CAS No. :105047-45-8 MDL No. :MFCD00038539
Formula : C21H24N2O4 Boiling Point : -
Linear Structure Formula :- InChI Key :YRKFMPDOFHQWPI-IBGZPJMESA-N
M.W : 368.43 Pubchem ID :7010557
Synonyms :

Safety of [ 105047-45-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 105047-45-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 105047-45-8 ]

[ 105047-45-8 ] Synthesis Path-Downstream   1~21

  • 1
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 105047-45-8 ]
  • [ 77128-73-5 ]
  • {(S)-2-[(S)-6-Amino-2-((S)-2-methylamino-3-phenyl-propionylamino)-hexanoylamino]-4-methyl-pentanoylamino}-acetic acid [ No CAS ]
  • 2
  • [ 29022-11-5 ]
  • [ 103478-62-2 ]
  • [ 108-24-7 ]
  • [ 105047-45-8 ]
  • [ 77128-73-5 ]
  • Ac-Lys-NMePhe-Gly-NMeLeu-NH2 [ No CAS ]
  • 3
  • [ 29022-11-5 ]
  • [ 136083-57-3 ]
  • [ 108-24-7 ]
  • [ 105047-45-8 ]
  • [ 77128-73-5 ]
  • (S)-3-((S)-2-{(S)-2-[(2-Acetylamino-acetyl)-methyl-amino]-3-phenyl-propionylamino}-6-amino-hexanoylamino)-succinamic acid [ No CAS ]
  • 4
  • [ 105047-45-8 ]
  • [ 95753-55-2 ]
  • [ 35737-15-6 ]
  • [ 157355-80-1 ]
  • JF-04-27 [ No CAS ]
  • 5
  • [ 105047-45-8 ]
  • [ 133081-26-2 ]
  • Fmoc-N-ε(Hynic-Boc)-L-lysine [ No CAS ]
  • 6-[6-[6-(<i>N</i>'-<i>tert</i>-butoxycarbonyl-hydrazino)-pyridine-3-carbonyl]-amino}-2-(9<i>H</i>-fluoren-9-ylmethoxycarbonylamino)-hexanoylamino]-2-(9<i>H</i>-fluoren-9-ylmethoxycarbonylamino)-hexanoic acid [ No CAS ]
  • 7
  • [ 918663-78-2 ]
  • [ 35661-60-0 ]
  • [ 105047-45-8 ]
  • [ 96402-49-2 ]
  • [ 1187754-81-9 ]
  • 8
  • [ 105047-45-8 ]
  • [ 58-85-5 ]
  • [ 146987-10-2 ]
  • 9
  • [ 258332-56-8 ]
  • C29H30NO4Pol [ No CAS ]
  • [ 71989-31-6 ]
  • [ 71989-23-6 ]
  • [ 105047-45-8 ]
  • [ 198561-07-8 ]
  • C44H70N8O10 [ No CAS ]
  • 10
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 71989-31-6 ]
  • [ 71989-18-9 ]
  • [ 35737-15-6 ]
  • [ 71989-35-0 ]
  • [ 71989-16-7 ]
  • [ 105047-45-8 ]
  • [ 77128-73-5 ]
  • [ 104090-92-8 ]
  • [ 1620146-28-2 ]
  • 11
  • [ 35661-40-6 ]
  • [ 105047-45-8 ]
  • [ 161420-87-7 ]
  • K-F-F-Dab [ No CAS ]
  • 12
  • [ 68858-20-8 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 104091-09-0 ]
  • [ 73731-37-0 ]
  • [ 105047-45-8 ]
  • [ 76-05-1 ]
  • [ 138775-22-1 ]
  • [ 158599-00-9 ]
  • Boc-Orn(Fmoc)-OH [ No CAS ]
  • C93H147IN20O21*2C2HF3O2 [ No CAS ]
  • 13
  • [ 68858-20-8 ]
  • [ 35661-60-0 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 104091-09-0 ]
  • [ 73731-37-0 ]
  • [ 105047-45-8 ]
  • [ 76-05-1 ]
  • [ 138775-22-1 ]
  • [ 158599-00-9 ]
  • Boc-Orn(Fmoc)-OH [ No CAS ]
  • C95H151IN20O23*2C2HF3O2 [ No CAS ]
  • 14
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 136083-57-3 ]
  • [ 104091-09-0 ]
  • [ 71989-23-6 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 71989-16-7 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 91000-69-0 ]
  • [ 96402-49-2 ]
  • [ 94744-50-0 ]
  • Y-(α-aminoisobutyroyl)-EGTFTSDYSIYLDKKAQRAFVNWLLA-(α-aminoisobutyroyl)-KYG-(β-(1-naphthyl)-alaninoyl)-LDF-NH2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
Solid phase peptide synthesis was performed on a CEM Liberty Peptide Synthesizer using standard Fmoc chemistry. TentaGel S Ram resin (1 g; 0.25 mmol/g) was swelled in NMP (10 ml) prior to use and transferred between tube and reaction vessel using DCM and NMP. Coupling (0148) An Fmoc-amino acid in NMP/DMF/DCM (1:1:1; 0.2 M; 5 ml) was added to the resin in a CEM Discover microwave unit together with HATU/DMF or COMU/DMF (0.5 M; 2 ml) and DIPEA/NMP (2.0 M; 1 ml). The coupling mixture was heated to 75° C. for 5 min while nitrogen was bubbled through the mixture. The resin was then washed with NMP (4×10 ml). Deprotection (0149) Piperidine/DMF (20percent; 10 ml) was added to the resin for initial deprotection and the mixture was heated by microwaves (30 sec; 40° C.). The reaction vessel was drained and a second portion of piperidine/NMP (20percent; 10 ml) was added and heated (75° C.; 3 min.) again. The resin was then washed with DMF (6×10 ml). Side Chain Acylation (0150) Fmoc-Lys(ivDde)-OH or alternatively another amino acid with an orthogonal side chain protective group was introduced at the position of the acylation. The N-terminal of the peptide backbone was then Boc-protected using Boc2O or alternatively by using a Boc-protected amino acid in the last coupling. While the peptide was still attached to the resin, the orthogonal side chain protective group was selectively cleaved using freshly prepared hydrazine hydrate (2-4percent) in NMP for 2×15 min. The unprotected lysine side chain was first coupled with Fmoc-Glu-OtBu or another spacer amino acid, which was deprotected with piperidine and acylated with a lipophilic moiety using the peptide coupling methodology as described above. Alternatively, the acylation moiety was introduced as a premade building block e.g. Fmoc-Lys(hexadecanoyl-gamma-Glu)-OH where gamm-Glu is the coupling of Glutamic acid through the side-chain. Abbreviations employed are as follows: COMU: 1-[(1-(cyano-2-ethoxy-2-oxoethylideneaminooxy)-dimethylamino-morpholinomethylene)]methanaminium hexaflourophosphate ivDde: 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)3-methyl-butyl Dde: 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-ethyl DCM: dichloromethane DMF: N,N-dimethylformamide (0151) DIPEA: diisopropylethylamine EtOH: ethanol Et2O: diethyl ether HATU: N-[(dimethylamino)-1H-1,2,3-triazol[4,5-b]pyridine-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide MeCN: acetonitrile NMP: N-methylpyrrolidone (0152) TFA: trifluoroacetic acid TIS: triisopropylsilane Cleavage (0153) The resin was washed with EtOH (3×10 ml) and Et2O (3×10 ml) and dried to constant weight at room temperature (r.t.). The crude peptide was cleaved from the resin by treatment with TFA/TIS/water (95/2.5/2.5; 40 ml, 2 h; r.t.). Most of the TFA was removed at reduced pressure and the crude peptide was precipitated and washed three times with diethylether and dried to constant weight at room temperature. HPLC Purification of the Crude Peptide (0154) The crude peptide was purified to greater than 90percent by preparative reverse phase HPLC using a PerSeptive Biosystems VISION Workstation equipped with a C-18 column (5 cm; 10 mum) and a fraction collector and run at 35 ml/min with a gradient of buffer A (0.1percent TFA, aq.) and buffer B (0.1percent TFA, 90percent MeCN, aq.). Fractions were analyzed by analytical HPLC and MS and relevant fractions were pooled and lyophilized. The final product was characterized by HPLC and MS. (0155) The synthesized compounds are shown in Table 1 and Table 2
  • 15
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 136083-57-3 ]
  • [ 104091-09-0 ]
  • [ 71989-23-6 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 77128-73-5 ]
  • [ 91000-69-0 ]
  • [ 116611-64-4 ]
  • C150H228N40O45 [ No CAS ]
YieldReaction ConditionsOperation in experiment
General procedure: tGLP-1 and its analogues 2?13 were all synthesized using general solid-phase peptide synthesis of N-Fmoc/tBu chemistry. 63Fmoc Rink Amide-MBHA resin (0.1 mmol) was added to a 25 ml peptide synthetic vessel and swollen with DMF for 40 min. After deprotected by 25percent piperidine in DMF, a solution of Fmoc-AA-OH (0.4 mmol), HATU (0.4 mmol), HoAt (0.4 mmol) and DIPEA (0.8 mmol) in DMF was added to the vessel. After reacted for 1 h, the resin was washed three times with DMF and three times with CH2Cl2, then qualitative ninhydrin testing was performed to monitor whether some free amino groups still existed on the resin ornot. If not, the resin was washed three times with DMF again and repeated the procedures of deprotection and coupling. Forthe coupling of some unnatural amino acids, NMM instead of DIPEA and NMP instead of DMF were used. Besides, the reaction time was prolonged to 4 h. Following the final deprotection of N-terminus, the target peptide was cleaved from resin with Reagent K (TFA/thioanisole/water/phenol/EDT, 82.5:5:5:5:2.5) for 2 h atroom temperature. After filtration, the residue solution was concentrated, precipitated with cold diethyl ether and centrifuged for three times. The residue was dissolved in water and purified by Waters 2545 preparative RP-HPLC system. Sephadex G-25 was used for the further purification to remove some short peptide impurities. The molecular mass of the target peptide was confirmed by MALDI-TOF. The purity of peptide was tested with analytical RP-HPLC, and the conditions were as follows: a linear gradient of 20percent mobile phase A and 80percent mobile phase B to 80percent mobile phase A and 20percent mobile phase B (A: acetonitrile containing 0.1percent TFA; B: H2O containing 0.1percent TFA) in 30 min, at a flow rate of 1 mL/minute with UV detection at 214 nm.
  • 16
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 136083-57-3 ]
  • [ 71989-23-6 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 91000-69-0 ]
  • [ 116611-64-4 ]
  • [ 193954-26-6 ]
  • C150H228N40O45 [ No CAS ]
YieldReaction ConditionsOperation in experiment
General procedure: tGLP-1 and its analogues 2-13 were all synthesized using general solid-phase peptide synthesis of N-Fmoc/tBu chemistry. 63Fmoc Rink Amide-MBHA resin (0.1 mmol) was added to a 25 ml peptide synthetic vessel and swollen with DMF for 40 min. After deprotected by 25% piperidine in DMF, a solution of Fmoc-AA-OH (0.4 mmol), HATU (0.4 mmol), HoAt (0.4 mmol) and DIPEA (0.8 mmol) in DMF was added to the vessel. After reacted for 1 h, the resin was washed three times with DMF and three times with CH2Cl2, then qualitative ninhydrin testing was performed to monitor whether some free amino groups still existed on the resin ornot. If not, the resin was washed three times with DMF again and repeated the procedures of deprotection and coupling. Forthe coupling of some unnatural amino acids, NMM instead of DIPEA and NMP instead of DMF were used. Besides, the reaction time was prolonged to 4 h. Following the final deprotection of N-terminus, the target peptide was cleaved from resin with Reagent K (TFA/thioanisole/water/phenol/EDT, 82.5:5:5:5:2.5) for 2 h atroom temperature. After filtration, the residue solution was concentrated, precipitated with cold diethyl ether and centrifuged for three times. The residue was dissolved in water and purified by Waters 2545 preparative RP-HPLC system. Sephadex G-25 was used for the further purification to remove some short peptide impurities. The molecular mass of the target peptide was confirmed by MALDI-TOF. The purity of peptide was tested with analytical RP-HPLC, and the conditions were as follows: a linear gradient of 20% mobile phase A and 80% mobile phase B to 80% mobile phase A and 20% mobile phase B (A: acetonitrile containing 0.1% TFA; B: H2O containing 0.1% TFA) in 30 min, at a flow rate of 1 mL/minute with UV detection at 214 nm.
  • 17
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 104091-09-0 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 71989-16-7 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 198561-07-8 ]
  • [ 684270-46-0 ]
  • C58H90N20O18 [ No CAS ]
  • 18
  • [ 942518-20-9 ]
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 104091-09-0 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 71989-16-7 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 198561-07-8 ]
  • C59H92N20O18 [ No CAS ]
  • 19
  • [ 1097192-04-5 ]
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 104091-09-0 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 71989-16-7 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 198561-07-8 ]
  • C60H94N20O18 [ No CAS ]
  • 20
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 71989-31-6 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 91000-69-0 ]
  • [ 135248-89-4 ]
  • [ 71989-31-6 ]
  • [ 116611-64-4 ]
  • [ 161420-87-7 ]
  • C84H118N24O21S2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
Coupling of the First Protected Amino Acid Residue to the Resin 0.5 g of 2-chlorotritylchloride resin (100-200 mesh, copoly(styrene-1% DVB) polymer matrix, Cat. No. 01-64-0114, Novabiochem, Merck Biosciences Ltd.) (Barlos et al. Tetrahedron Lett. 1989, 30, 3943-3946) (1.4 mMol/g, 0.7 mmol) was filled into a dried flask. The resin was suspended in CH2Cl2 (2.5 ml) and, allowed to swell at room temperature under constant stirring for 30 min. The resin was treated with 0.49 mMol (0.7 eq) of the first suitably protected amino acid residue and 488 mul (4 eq) of diisopropylethylamine (DIEA) in CH2Cl2 (2.5 ml), the mixture was shaken at 25 C. for 4 hours. The resin was shaken (CH2Cl2/MeOH/DIEA: 17/2/1), 30 ml for 30 min; then washed in the following order with CH2Cl2 (1×), DMF (1×), CH2Cl2 (1×), MeOH (1×), CH2Cl2 (1×), MeOH (1×), CH2Cl2 (2×), Et2O (2×) and dried under vacuum for 6 hours. Loading was typically 0.6-0.9 mMol/g. The following preloaded resin was prepared: Fmoc-Pro-2-chlorotritylresin. Synthesis of the Fully Protected Peptide Fragment The synthesis was carried out on a Syro-peptide synthesizer (MultiSynTech GmbH) using 24 to 96 reaction vessels. In each vessel were placed approximately 60 mg (weight of the resin before loading) of the above resin. The following reaction cycles were programmed and carried out: Steps 3 to 6 are repeated to add each amino-acid. Analytical Method: Analytical HPLC retention times (RT, in minutes) were determined using a Jupiter Proteo 90 A column, 150×2.0 mm, (cod. 00E-4396-B0-Phenomenex) with the following solvents A (H2O+0.1% TFA) and B (CH3CN+0.1% TFA) and the gradient: 0 min: 95% A, 5% B; 0.5 min: 95% A, 5% B; 20 min: 40% A, 60% B; 21 min: 0% A, 100% B; 23 min: 0% A, 100% B; 23.1 min: 95% A, 5% B; 31 min: 95% A, 5% B. Formation of Disulfide beta-Strand Linkage After formation of the disulfide beta-strand linkage, the resin was suspended in 1 ml (0.14 mMol) of 1% TFA in CH2Cl2 (v/v) for 3 minutes and filtered, and the filtrate was neutralized with 1 ml (1.15 mMol) of 20% DIEA in CH2Cl2 (v/v). This procedure was repeated twice to ensure completion of the cleavage. The resin was washed three times with 1 ml of CH2Cl2. The CH2Cl2 layer was evaporated to dryness. The volatiles were removed and 8 ml dry DMF were added to the tube. Then 2 eq. of HATU in dry DMF (1 ml) and 4 eq. of DIPEA in dry DMF (1 ml) were added to the peptide, followed by stirring for 16 h. The volatiles were evaporated to dryness. The crude cyclised peptide was dissolved in 7 ml of CH2Cl2 and extracted with 10% acetonitrile in H2O (4.5 ml) three times. The CH2Cl2 layer was evaporated to dryness. To deprotect the peptide fully, 3 ml of cleavage cocktail TFA:TIS:H2O (95:2.5:2.5) were added, and the mixture was kept for 2.5 h. The volatiles were evaporated to dryness and the crude peptide was dissolved in 20% AcOH in water (7 ml) and extracted with isopropyl ether (4 ml) for three times. The aqueous layer was collected and evaporated to dryness, and the residue was purified by preparative reverse phase HPLC. After lyophilisation the products were obtained as white powders and analysed by the HPLC-ESI-MS analytical method described above. The analytical data comprising purity after preparative HPLC and ESI-MS are given. The peptide was synthesized starting with the amino acid L-Pro which was grafted to the resin. Starting resin was Fmoc-Pro-2-chlorotrityl resin, which was prepared as described above. The linear peptide was synthesized on solid support according to the procedure described above in the following sequence: Resin-Pro-DPro-Lys-Gln-Tyr-Cys-Tyr-Arg-Dab-DPro-Ala-Ser-Cys-Ala-His-Tyr. A disulfide beta-strand linkage was introduced as described above. The product was cleaved from the resin, cyclized, deprotected and purified as indicated by preparative reverse phase LC-MS. After lyophilisation the product was obtained as white powder and analysed by the HPLC-ESI-MS analytical method described above ([M+2H]2+: 933.1; RT: 10.47; UV-purity: 72%).
  • 21
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 71989-31-6 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 91000-69-0 ]
  • [ 135248-89-4 ]
  • [ 71989-31-6 ]
  • [ 116611-64-4 ]
  • [ 161420-87-7 ]
  • C90H122N24O22S2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
Coupling of the First Protected Amino Acid Residue to the Resin 0.5 g of 2-chlorotritylchloride resin (100-200 mesh, copoly(styrene-1% DVB) polymer matrix, Cat. No. 01-64-0114, Novabiochem, Merck Biosciences Ltd.) (Barlos et al. Tetrahedron Lett. 1989, 30, 3943-3946) (1.4 mMol/g, 0.7 mmol) was filled into a dried flask. The resin was suspended in CH2Cl2 (2.5 ml) and, allowed to swell at room temperature under constant stirring for 30 min. The resin was treated with 0.49 mMol (0.7 eq) of the first suitably protected amino acid residue and 488 mul (4 eq) of diisopropylethylamine (DIEA) in CH2Cl2 (2.5 ml), the mixture was shaken at 25 C. for 4 hours. The resin was shaken (CH2Cl2/MeOH/DIEA: 17/2/1), 30 ml for 30 min; then washed in the following order with CH2Cl2 (1×), DMF (1×), CH2Cl2 (1×), MeOH (1×), CH2Cl2 (1×), MeOH (1×), CH2Cl2 (2×), Et2O (2×) and dried under vacuum for 6 hours. Loading was typically 0.6-0.9 mMol/g. The following preloaded resin was prepared: Fmoc-Pro-2-chlorotritylresin. Synthesis of the Fully Protected Peptide Fragment The synthesis was carried out on a Syro-peptide synthesizer (MultiSynTech GmbH) using 24 to 96 reaction vessels. In each vessel were placed approximately 60 mg (weight of the resin before loading) of the above resin. The following reaction cycles were programmed and carried out: Steps 3 to 6 are repeated to add each amino-acid. Analytical Method: Analytical HPLC retention times (RT, in minutes) were determined using a Jupiter Proteo 90 A column, 150×2.0 mm, (cod. 00E-4396-B0-Phenomenex) with the following solvents A (H2O+0.1% TFA) and B (CH3CN+0.1% TFA) and the gradient: 0 min: 95% A, 5% B; 0.5 min: 95% A, 5% B; 20 min: 40% A, 60% B; 21 min: 0% A, 100% B; 23 min: 0% A, 100% B; 23.1 min: 95% A, 5% B; 31 min: 95% A, 5% B. Formation of Disulfide beta-Strand Linkage After formation of the disulfide beta-strand linkage, the resin was suspended in 1 ml (0.14 mMol) of 1% TFA in CH2Cl2 (v/v) for 3 minutes and filtered, and the filtrate was neutralized with 1 ml (1.15 mMol) of 20% DIEA in CH2Cl2 (v/v). This procedure was repeated twice to ensure completion of the cleavage. The resin was washed three times with 1 ml of CH2Cl2. The CH2Cl2 layer was evaporated to dryness. The volatiles were removed and 8 ml dry DMF were added to the tube. Then 2 eq. of HATU in dry DMF (1 ml) and 4 eq. of DIPEA in dry DMF (1 ml) were added to the peptide, followed by stirring for 16 h. The volatiles were evaporated to dryness. The crude cyclised peptide was dissolved in 7 ml of CH2Cl2 and extracted with 10% acetonitrile in H2O (4.5 ml) three times. The CH2Cl2 layer was evaporated to dryness. To deprotect the peptide fully, 3 ml of cleavage cocktail TFA:TIS:H2O (95:2.5:2.5) were added, and the mixture was kept for 2.5 h. The volatiles were evaporated to dryness and the crude peptide was dissolved in 20% AcOH in water (7 ml) and extracted with isopropyl ether (4 ml) for three times. The aqueous layer was collected and evaporated to dryness, and the residue was purified by preparative reverse phase HPLC. After lyophilisation the products were obtained as white powders and analysed by the HPLC-ESI-MS analytical method described above. The analytical data comprising purity after preparative HPLC and ESI-MS are given. The peptide was synthesized starting with the amino acid L-Pro which was grafted to the resin. Starting resin was Fmoc-Pro-2-chlorotrityl resin, which was prepared as described above. The linear peptide was synthesized on solid support according to the procedure described above in the following sequence: Resin-Pro-DPro-Lys-Gln-Tyr-Cys-Tyr-Arg-Dab-DPro-Ala-Ser-Cys-Tyr-His-Tyr. A disulfide beta-strand linkage was introduced as described above. The product was cleaved from the resin, cyclized, deprotected and purified as indicated by preparative reverse phase LC-MS. After lyophilisation the product was obtained as white powder and analysed by the HPLC-ESI-MS analytical method described above ([M+2H]2+: 978.6; RT: 10.95; UV-purity: 82%).
Recommend Products
Same Skeleton Products

Technical Information

Historical Records
; ;